Clinical Trials on Postmenopausal Women With Moderate Vasomotor Symptoms in Poland

Total 9 results

Warner Chilcott

Completed

Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover

Postmenopausal Women With Osteoporosis

Spain, Australia, Belgium, Denmark, Finland, Italy, Poland, Sweden
Celltrion

Completed

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

Postmenopausal Women With Osteoporosis

Estonia, Ukraine, Poland, Latvia
Sandoz
Hexal AG

Completed

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Postmenopausal Women With Osteoporosis

United States, Bulgaria, Czechia, Japan, Poland, Spain
mAbxience Research S.L.

Active, not recruiting

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)

Postmenopausal Women With Osteoporosis

Poland, Serbia, Bulgaria, Georgia, Estonia, Hungary, Latvia, Mexico
Amgen

Completed

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (ARCH)

Postmenopausal Women With Osteoporosis

United States, Canada, Denmark, France, Germany, Italy, Belgium, Colombia, Czechia, Mexico, Poland, Russian Federation, Netherlands, Hungary, Peru, Turkey, Taiwan, Spain, Hong Kong, Austria, Slovakia, United Kingdom, South Africa, Aus... and more
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

United States, Switzerland, Canada, Poland, Italy, Germany, Portugal, Norway, Slovakia, Czechia
Bayer

Completed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause (OASIS-3)

Hot Flashes | Vasomotor Symptoms Associated With Menopause

Belgium, United States, Poland, Spain, Bulgaria, Finland, Canada, Denmark, United Kingdom
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
Noblewell
Medical Research Agency, Poland; Leszek Giec Upper-Silesian Medical Centre...

Terminated

Efficacy of Amantadine Treatment in COVID-19 Patients (TITAN)

Patients With Moderate or Severe COVID-19

Poland

Clinical Trials on Postmenopausal Women With Moderate Vasomotor Symptoms in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations